<i id='C94EF745E1'><strike id='C94EF745E1'><tt id='C94EF745E1'><pre id='C94EF745E1'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
BioMarin wins approval for gene therapy to treat hemophilia A 
Argenx readies a blockbuster opportunity with drug for autoimmune disease 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Neuroscience’s long legacy of racism 
Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections 
Virtual Event: March of the Biosimilars 
Hepatitis C has a cure — but many Americans still lack access to it 
CVS Caremark has created a new ploy: the drug ‘rebate credit’ 
After affirmative action ruling, medical educators look to 'holistic review' 
Takeaways from AdvaMed, the largest medical devices conference 
Sports medicine is finally prioritizing gender equality 
STAT Readout Newsletter: Today in biotech, life science news 
Trump demands the U.S. pay no more for drugs than other countries … again 
Readout LOUD podcast: Merger Mondays, Ozempic panic 
Heart attack and stroke risk calculators need revising 
